Cardiovascular, ophthalmologic and otolaryngologic medical device innovations – Progress report 2021 from the Twenty20 consortium RESPONSE

Niels Grabow,Volkmar Senz,Klaus-Peter Schmitz

doi:10.1515/cdbme-2021-2181

Abstract

Abstract The coordinated research project “RESPONSE - Partnership for Innovation in Implant Technology”, which is one of ten BMBF-funded research consortia within the program “Twenty20 - Partnership for Innovation”, is active in the field of medical device innovation. The consortium is currently in the process of unfolding its transfer phase. This involves a portfolio of key innovations for novel medical devices, technologies and processes. Also, RESPONSE is aiming at participative technology development, integrating perspectives of patients, developers, as well as systems and innovation researchers. Particular challenges are arising from the current re-prioritization and re-scheduling of project roadmaps in order to manage and alleviate the effects of the corona crisis.

Highlights

Since its start in 2014, the coordinated research project “RESPONSE – Partnership for Innovation in Implant Technology”, which is one of ten BMBF-funded research consortia within the program “Twenty20 – Partnership for Innovation”, has been active in the field of medical device innovation
RESPONSE is currently in the process of unfolding its transfer phase, with an emphasis on ex vivo and preclinical in vivo testing of novel medical device concepts [1, 2]. This involves a portfolio of medical device innovations, technologies and processes, aiming beyond the completion of the funding period in 2021/22: (i) covered stents and absorbable scaffolds, (ii) electrospun nanofibrous nonwovens for transcatheter heart valves for cardiovascular medicine, (iii) glaucoma microstents and (iv) Eustachian tube stents for ophthalmic and otolaryngologic application, respectively (Figure 1)
Smart implant concepts are being pursued towards reduced implantation trauma [14], as well as novel diagnostic and therapeutic functions

Summary

Current Situation

RESPONSE is currently in the process of unfolding its transfer phase, with an emphasis on ex vivo and preclinical in vivo testing of novel medical device concepts [1, 2]. This involves a portfolio of medical device innovations, technologies and processes, aiming beyond the completion of the funding period in 2021/22: (i) covered stents and absorbable scaffolds, (ii) electrospun nanofibrous nonwovens for transcatheter heart valves for cardiovascular medicine, (iii) glaucoma microstents and (iv) Eustachian tube stents for ophthalmic and otolaryngologic application, respectively (Figure 1)

Background

Prospect